The Immuno-Oncology Revolution: A Guide for Health-System Pharmacists in Renal Cell Carcinoma
Jointly provided by
Impact Education, LLC    
This activity is supported by independent educational grants from Eisai and Merck & Co., Inc.

Sunday, December 8, 2019
4:00 PM - 5:00 PM
Mandalay Bay Convention Center
Room: South Pacific CD, North Convention Center
Las Vegas, NV
A Satellite Symposium conducted at the 2019 ASHP Midyear Clinical Meeting and Exhibition.




Preregistration is for planning purposes only and seating will be available on a first come, first served basis.
Learn about
  • Current and emerging treatments for advanced renal cell carcinoma (RCC)
  • Consideration of IO combination therapies in the treatment of advanced RCC
  • When immunotherapy should be considered as a treatment option for patients with advanced RCC
DISTINGUISHED FACULTY PRESENTERS
Christopher A. Fausel, PharmD, MHA, BCOP
Clinical Manager, Oncology Pharmacy
Indiana University Simon Cancer Center
Sumanta Kumar Pal, MD
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center
WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of health-system pharmacists attending the 2019 ASHP Midyear Clinical Meeting and Exhibition.

STATEMENT OF NEED / PROGRAM OVERVIEW

Renal cell carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and is the most common form of kidney cancer observed in the United States. About 70% of patients have clear cell RCC and approximately one-third of these present with advanced (or metastatic) disease. The natural history of disease for patients with advanced RCC can vary widely from a few months to many years depending on the clinical, pathologic, laboratory, and radiographic features of disease, as well as the response to therapy. The five-year overall survival rate is approximately 12%.

Health-system pharmacists (HSPs) often serve as patient care providers in acute and ambulatory care settings and frequently act as the intermediary between physicians and patients; a position that provides unique insights into treatment-specific needs of patients with advanced RCC. This activity will 1) educate HSPs the rationale for consideration of IO combination therapies in the treatment of RCC, 2) increase knowledge of when immunotherapy should be considered as a treatment option for patients with RCC, and 3) apply strategies for early detection and management of treatment-related adverse events in RCC patients.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Review current and emerging treatments for advanced RCC
  • Discuss the rationale for consideration of IO combination therapies in the treatment of advanced RCC
  • Identify when immunotherapy should be considered as a treatment option for patients with advanced RCC including patient selection, optimal drug combinations, and sequencing
  • Employ early detection and management strategies for treatment-emergent adverse events in patients with advanced RCC
AGENDA

Date and Time
Sunday, December 8, 2019
4:00 PM - 5:00 PM
Mandalay Bay Convention Center
Room: South Pacific CD, North Convention Center
Las Vegas, NV

4:00 PM Opening Comments
Christopher A. Fausel, PharmD, MHA, BCOP
4:05PM Examining the Clinical Benefits of Immuno-Oncology Agents for Renal Cell Carcinoma
Sumanta Kumar Pal, MD
4:30 PM Care Management Strategies to Enhance Overall Outcomes for Patients Requiring Immuno-Oncology Agents for RCC
Christopher A. Fausel, PharmD, MHA, BCOP
4:45 PM Case Study
Christopher A. Fausel, PharmD, MHA, BCOP
4:55 PM Faculty Panel Discussion and Audience Q&A
Faculty Panel
5:00 PM Adjournment

Continuing Pharmacy Education
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - tbd

Type of Activity: Knowledge

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from CEcertificate@pimed.com within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. Pharmacist have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act
♿ Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.

Meeting Information
Preregistration is for planning purposes only and seating will be available on a first come, first served basis.

Fee Information
Please note: No additional fee is required to attend this CPE activity; however, registration to the 2019 ASHP Midyear Clinical Meeting and Exhibition is required.

Pre-registration will close at 12:00 pm on December 7, 2019.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.